在城市安全网队列中扩散大B细胞淋巴瘤结局:功能状态,临床风险和治疗可行性
Aye Thida1, Erfan Nasirikhaneghah2, Edwin Chiu3
1Department of Hematology-Medical Oncology, NewYork-Presbyterian/Weill Cornell Medicine, New York, NY, USA.
Leukemia & lymphoma
|March 3, 2026
概括
在城市安全网医院的扩散性大B细胞淋巴瘤 (DLBCL) 患者的生存率主要受到功能状态和临床风险的影响. 治疗可行性也会影响这种服务不足的人群的整体存活率 (OS).
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 公共卫生 公共卫生
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 的结果是异质的.
- 美国城市安全网医院对DLBCL患者的数据有限.
研究的目的:
- 在城市安全网医院对DLBCL患者的整体存活率 (OS) 相关的因素进行评估.
- 调查功能状态,风险分层,并发病,艾滋病毒状况,保险和治疗可行性与OS之间的关联.
主要方法:
- 对62名成人DLBCL患者 (2013-2023) 的回顾性队列研究.
- 分析了临床因素与整体存活率 (OS) 之间的关联.
主要成果:
- 一年后的操作系统为62%.
- 糟糕的绩效状态 (ECOG ≥2) 和更高的修订国际预测指数得分与劣质的OS有关.
- 仅仅支持性护理与更糟糕的生存率有关;保险和起源细胞不是OS的独立预测因素.
结论:
- 功能状态,临床风险和治疗可行性是安全网DLBCL队列中生存的主要驱动因素.
- 这些因素对于在服务不足的人群中管理DLBCL至关重要.
相关概念视频
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer Survival Analysis
863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863

